Oncotarget is a publishing company that publishes journals and distributes them on their online platform. Access to these publications is for free for all the websites clients. The releases are usually made on a weekly basis depending on the demand for the particular journals. Trending issues and topics at times determine the journal that will be published on Oncotargets website. The journals availed for its readers tend to cut across various disciplines hence the reason why the site is referred to as multidisciplinary. Over the years, Oncotarget has been striving to maximize the potential impact its published materials have on its audience while at the same time providing an insightful view to current issues within the scientific realm.
There has been an ongoing urgency by Oncotarget to abolish the boundaries within the biomedical specialties.With the leadership of the renowned scientists, Oncotarget has been providing researchers with journals that are aimed at contributing significantly to the development of sciences to one day achieve a life free from diseases.Oncotarget has been liaising closely with exemplary high-profile scientific indexes with the aim of providing all relevant scientific publications robustly to its clients. This has been well demonstrated by the collaboration between Oncotarget and IntegraGen.IntegraGen is a firm that has over the years specialized in the transformation of samples of biological data to genomic information and at times diagnostic equipment for Oncology.
Recently, news of the publishing of the analysis of tumor samples from patients who were undergoing the NEW EPOC clinical trial surfaced. Research carried out by IntegraGen show of a relationship between miR-31-3p expression and anti-EGFR treatment. There is the need to develop a tool that is capable of distinguishing patients who can benefit from this treatment option from those who can’t.As a business, Oncotarget doesn’t plan on being left behind with the 21st century’s technological wave. Currently, the firm is adopting new indexing algorithms aimed at the facilitation of dissemination of their scholarly Journals to relevant personnel within the sizeable medical research factions. Due to the increasing demand for Oncotargets journals, the company has shifted from publishing journals to their website one a week to the current rate of two Journals each week.
Research for the most suitable cancer medicine has been carried out since time in memorial, and Dr. Clay Siegall has been fully involved in the various scientific research processes that have been carried out by scientists, in the course coming up with a solution to the destructive ailment that has claimed more lives than any other disease. While undertaking different research processes, Dr. Clay realized that there was a great need to ensure that cancer patients are able to access medication that helps to lower the side effect of the ailment.
His previous life experience combined with the desire of ensuring that a final solution is developed to cure the complication, Dr. Clay Siegall helped to co-found Seattle Genetics. The research center was founded back in 1998, and it was originally established as a biotech company that would, in the end, help to spearhead research into different methods of curing cancer. Initially, the biotech company was a small medical facility startup, and most of the work was carried out using limited resources. Additionally, researchers at the organization were not as many compared to the current situation.
Through continuous effort and never giving up, Clay Siegall managed to prove to the world that his firm can successfully undertake in-depth research in cancer treatment and even come up with the most suitable medication. Seattle Genetics has managed to manufacture over 20 different types of drugs that have been distributed in the market to help in the treatment of cancer. Seattle Genetics, under the management of Clay Siegall, has managed to push through the challenges of the business world, and at the moment it is recognized as one of the largest biotechnology companies that helps to advance research on cancer treatment.
Clay Siegall studied medicine at the University of Maryland, and it is in the course of his studies that he realized the great passion that he had towards cancer research and treatment. He also realized that the current advancement in technology would help him achieve his dream of availing a suitable medication for treating various genetic related conditions.
Since his father had cancer, he loathed the manner in which chemotherapy was being administered at that time, Clay Siegall became motivated more than ever to ensure that the new methods are invented to help cancer patients access medication in a more humane manner.